ABSTRACT:
A common prostaglandin analogue for glaucoma and ocular hypertension patients is Travoprost, which lowers intraocular pressure. The prostaglandin FP receptors, which are found in the ciliary muscle and the trabecular meshwork, are which causes the ocular hypotension, Travoprost is more effective than timolol at lowering intraocular pressure, although there is typically no difference when comparing it to other prostaglandin analog. This article discusses the development and validation of an HPLC method for analyzing a fixed-dose combination of timolol and travoprost, which has demonstrated similar intraocular pressure-lowering effectiveness as when the drugs are used separately. Following ICH Guidelines, the HPLC validation process involves evaluating parameters such as accuracy, specificity, linearity, range, detection and quantification limits, robustness, and system suitability. In the frame of this information, this review aims to provide the compilation and discussion of hplc methods published in the literature for estimation of Travoprost in single or combined dosage form in pharmaceutical dosage forms. the following review discusses the comparative use of hplc by UV/PDA methodologies for Travoprost estimation. The current compilation can be effectively used to enhance Travoprost future analytical research demands.
Cite this article:
V.Swetha, V.Sahithi, B.Anusha. A review on HPLC Methods for Estimation of Travoprost in Combined and Single Pharmaceutical formulation and Bulk. IJRPAS, June 2025; 4 (6): 96-102.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4610
1.
Stewart WC, Stewart JA, Nelson LA. Ocular
surface disease in patients with ocular hypertension and glaucoma. Current eye
research. 2011 May 1;36(5):391-8.
2.
Fuchsjäger-Mayrl G, Wally B, Georgopoulos
M, Rainer G, Kircher K, Buehl W, Amoako-Mensah T, Eichler HG, Vass C,
Schmetterer L. Ocular blood flow and systemic blood pressure in patients with
primary open-angle glaucoma and ocular hypertension. Investigative
ophthalmology & visual science. 2004 Mar 1;45(3):834-9.
3.
Reardon G, Kotak S, Schwartz GF. Objective
assessment of compliance and persistence among patients treated for glaucoma
and ocular hypertension: a systematic review. Patient preference and adherence.
2011 Sep 23:441-63.
4.
Olthoff CM, Schouten JS, van de Borne BW,
Webers CA. Noncompliance with ocular hypotensive treatment in patients with
glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005
Jun 1;112(6):953-61.
5.
Wadhwani M, Mishra SK, Angmo D, Velpandian
T, Sihota R, Kotnala A, Bhartiya S, Dada T. Evaluation of physical properties
of generic and branded Travoprost formulations. Journal of Current Glaucoma
Practice. 2016 Aug 5;10(2):49.
6.
Sorbera LA, Castaner J. Travoprost. Drugs
of the Future. 2000;25(1).
7.
Lim KS, Nau CB, O'Byrne MM, Hodge DO,
Toris CB, McLaren JW, Johnson DH. Mechanism of action of Bimatoprost,
Latanoprost, and Travoprost in healthy subjects: a crossover study.
Ophthalmology. 2008 May 1;115(5):790-5.
8.
Stahl E, Bremond-Gignac D, Landry T,
Curtis M, Gedif K, Al Shahwan S, Dixon ER. Pharmacokinetics and safety of
travoprost 0.004% ophthalmic solution preserved with polyquad in pediatric
patients with glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2017
Jun 1;33(5):361-5.
9.
Hanai TT. HPLC: a practical guide. Royal
Society of Chemistry; 2007 Oct 31.
10.
Moldoveanu SC, David V. Selection of the
HPLC method in chemical analysis. Elsevier; 2016 Nov 1.
11.
Pujari SR, Mahajan SS. DEVELOPMENT OF
STABLE FORMULATION OF TRAVOPROST OPHTHALMIC SOLUTION 0.004%.
12.
Kumari VR, Venkateswarrao P, Sunitha A,
Keerthy K. Stability indicating RP-HPLC method for simultaneous estimation of
travopost and timolol in bulk and pharmaceutical dosage forms. IJPRR.
2015;5(3):176-82.
13.
FEI Luhua, WU Juan , FEI Hanyu.
Determination of the Related Substances of Travoprost in Travoprost and Timolol
Maleate Eye Drops by HPLC, Herald of Medicine ›› 2023, Vol. 42 ›› Issue (3) :
411-415.
14.
Jothieswari D, Reddy BC, Soniya S,
Dharshini Y, Roja K. Method development and validation of simultaneous
estimation of timolol maleate and travoprost in bulk and in pharmaceutical
dosage form by UV-spectroscopy. J Pharm Bio. 2017;7:22-32.